Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients

Abstract

BACKGROUND AND AIMS:

Assessment of the potential predictive value of serum inducible protein-10 chemokine (IP-10) in the clearance of HCV in Egyptian patients with and without treatment.

MATERIALS AND METHODS:

Ninety Egyptian individuals were involved in the current study where, 20 patients (23%) were chronic HCV (positive HCV antibodies and positive HCV RNA without treatment, 20 (22%) were healthy individuals (negative for both HCV antibodies and HCV RNA, 20 (22%) were natural clearance (positive HCV antibodies and negative for HCV RNA without treatment), 20 (22%) were achieved SVR after treatment (responders group, HCV positive and negative for HCV RNA after treatment) and 10 (11%) were non responders (positive HCV antibodies and still positive HCV RNA after treatment). HCV RNA was quantitated by real time PCR and serum IP10 level was measured by commercial ELISA kit. All biochemical and hematological examinations included liver function, CBC and alphefeto protein were assessed.

RESULTS:

The mean serum levels of IP-10 were significantly higher ( $p<$ 0.001) in CHC patients (345.4 $\pm$ 100) pg/ml compared with healthy control group (101.5 $\pm$ 31.4) and natural clearance group (103.2 $\pm$ 40.7). Also serum levels of IP-10 was significantly elevated in non-responders group (257.4 $\pm$ 52.5) compared with each of SVR group (103.5 $\pm$ 43.5) ( $p<$ 0.001) and healthy group (101.5 $\pm$ 31.4), ( $p<$ 0.001). Prediction of a clinical response based on a IP10 chemokine revealed high sensitivity (93%), specificity (96%), negative predictive value (96%), and area under curve is (1.00). Moreover, there is no correlation (( $R=$ 0.05), $P$ value $p<$ 0.795) between serum level of IP-10 and HCV viral load.

CONCLUSION:

IP10 is a useful non-invasive biomarker for viral clearance and might be used to apply patients according to the predictable treatment outcome. Accordingly, patients who are unlikely to respond to treatment would avoid unnecessary exposure to medication that is related with high morbidity.